177 related articles for article (PubMed ID: 32398112)
1. Modified Sijunzi decoction in the treatment of ulcerative colitis in the remission phase: study protocol for a series of N-of-1 double-blind, randomised controlled trials.
Chen YM; Deng JM; Wen Y; Chen B; Hou JT; Peng B; Zhang SJ; Mi H; Jiang QL; Wu XL; Liu FB; Chen XL
Trials; 2020 May; 21(1):396. PubMed ID: 32398112
[TBL] [Abstract][Full Text] [Related]
2. Sijunzi decoction, a classical Chinese herbal formula, improves fatigue symptoms with changes in gut microbiota in chronic fatigue syndrome: A randomized, double-blind, placebo-controlled, multi-center clinical trial.
Dai L; Liu Z; Zhou W; Zhang L; Miao M; Wang L; Hua H; Wang B; Ji G
Phytomedicine; 2024 Jul; 129():155636. PubMed ID: 38640860
[TBL] [Abstract][Full Text] [Related]
3. Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial.
Shen Z; Zheng K; Zou J; Gu P; Xing J; Zhang L; Zhu L; Shen H
Trials; 2021 Jan; 22(1):55. PubMed ID: 33441157
[TBL] [Abstract][Full Text] [Related]
4. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
Sun J; Yuan Y
Adv Ther; 2016 Mar; 33(3):400-9. PubMed ID: 26898569
[TBL] [Abstract][Full Text] [Related]
5. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
Sun J; Yuan Y
Adv Ther; 2016 Mar; 33(3):410-22. PubMed ID: 26905266
[TBL] [Abstract][Full Text] [Related]
6. Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis--a double-blind, double-dummy study.
Langhorst J; Varnhagen I; Schneider SB; Albrecht U; Rueffer A; Stange R; Michalsen A; Dobos GJ
Aliment Pharmacol Ther; 2013 Sep; 38(5):490-500. PubMed ID: 23826890
[TBL] [Abstract][Full Text] [Related]
7. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
Kruis W; Kiudelis G; Rácz I; Gorelov IA; Pokrotnieks J; Horynski M; Batovsky M; Kykal J; Boehm S; Greinwald R; Mueller R;
Gut; 2009 Feb; 58(2):233-40. PubMed ID: 18832520
[TBL] [Abstract][Full Text] [Related]
8. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Kamm MA; Lichtenstein GR; Lyne A; Butler T; Joseph RE
Aliment Pharmacol Ther; 2007 Jul; 26(2):205-15. PubMed ID: 17593066
[TBL] [Abstract][Full Text] [Related]
9. Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial.
Turner D; Yerushalmi B; Kori M; Broide E; Mozer-Glassberg Y; Shaoul R; Kolho KL; Shteyer E; Shamaly H; Ledder O; Cohen S; Peleg S; On A; Levine A
J Crohns Colitis; 2017 May; 11(5):527-533. PubMed ID: 28453754
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: a double-blinded and randomized study.
Gong Y; Zha Q; Li L; Liu Y; Yang B; Liu L; Lu A; Lin Y; Jiang M
J Ethnopharmacol; 2012 Jun; 141(2):592-8. PubMed ID: 21911045
[TBL] [Abstract][Full Text] [Related]
11. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.
Vecchi M; Meucci G; Gionchetti P; Beltrami M; Di Maurizio P; Beretta L; Ganio E; Usai P; Campieri M; Fornaciari G; de Franchis R
Aliment Pharmacol Ther; 2001 Feb; 15(2):251-6. PubMed ID: 11148445
[TBL] [Abstract][Full Text] [Related]
12. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
Gross V; Bunganic I; Belousova EA; Mikhailova TL; Kupcinskas L; Kiudelis G; Tulassay Z; Gabalec L; Dorofeyev AE; Derova J; Dilger K; Greinwald R; Mueller R;
J Crohns Colitis; 2011 Apr; 5(2):129-38. PubMed ID: 21453882
[TBL] [Abstract][Full Text] [Related]
13. Randomised clinical trial: Efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter, randomized, and double-blind clinical trial of patients with moderately active ulcerative colitis.
Shen H; Zhang S; Zhao W; Ren S; Ke X; Gu Q; Tang Z; Xie J; Chen S; Chen Y; Zou J; Zhang L; Shen Z; Zheng K; Liu Y; Gu P; Cheng J; Hu J; Zhu L
Biomed Pharmacother; 2021 Jul; 139():111580. PubMed ID: 33857914
[TBL] [Abstract][Full Text] [Related]
14. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
Lichtenstein GR; Zakko S; Gordon GL; Murthy U; Sedghi S; Pruitt R; Merchant K; Bortey E; Forbes WP
Aliment Pharmacol Ther; 2012 Jul; 36(2):126-34. PubMed ID: 22617015
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
Nguyen NH; Fumery M; Dulai PS; Prokop LJ; Sandborn WJ; Murad MH; Singh S
Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):742-753. PubMed ID: 30122356
[TBL] [Abstract][Full Text] [Related]
16. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
[TBL] [Abstract][Full Text] [Related]
17. Effect of Kangfuxin Liquid enema combined with mesalazine on gestational outcomes and quality of life in child-bearing female with active ulcerative colitis: A protocol for randomized, double-blind, controlled trial.
Wang T; Lu H; Li F; Zhang Q
Medicine (Baltimore); 2021 Feb; 100(5):e23915. PubMed ID: 33592844
[TBL] [Abstract][Full Text] [Related]
18. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
Rembacken BJ; Snelling AM; Hawkey PM; Chalmers DM; Axon AT
Lancet; 1999 Aug; 354(9179):635-9. PubMed ID: 10466665
[TBL] [Abstract][Full Text] [Related]
19. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.
D'Haens GR; Sandborn WJ; Zou G; Stitt LW; Rutgeerts PJ; Gilgen D; Jairath V; Hindryckx P; Shackelton LM; Vandervoort MK; Parker CE; Muller C; Pai RK; Levchenko O; Marakhouski Y; Horynski M; Mikhailova E; Kharchenko N; Pimanov S; Feagan BG
Aliment Pharmacol Ther; 2017 Aug; 46(3):292-302. PubMed ID: 28568974
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and safety of modified Sijunzi decoction for the treatment of ulcerative colitis: A protocol for a systematic review and meta-analysis.
Tian SW; Zhang YL; Wang B; Liu JP; Wang C; Zhang J
Medicine (Baltimore); 2021 Jan; 100(4):e23703. PubMed ID: 33530172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]